Micrornas targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Jiao, Long R ^a   Frampton, Adam E ^a   Jacob, Jimmy ^a   Pellegrino, Loredana ^a   Krell, Jonathan ^a   Giamas, Georgios ^a   Tsim, Nicole ^a   Vlavianos, Panagiotis ^a   Cohen, Patrizia ^a   Ahmad, Raida ^a   Keller, Andreas ^b   Habib, Nagy A ^a   Stebbing, Justin ^a   Castellano, Leandro ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; K RAS PROTEIN; MICRORNA; MIR 126; MIR 16; PROTEIN BCL 2; PROTEIN CRK; PROTEIN LET 7D; TUMOR PROTEIN; UNCLASSIFIED DRUG; LUCIFERASE; RAS PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BENIGN TUMOR; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; ONCOGENE; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATIC BENIGN CYSTIC TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROUS MICROCYSTIC ADENOMA; TERTIARY HEALTH CARE; TISSUE SECTION; TRANSCRIPTION REGULATION; UPREGULATION; APOPTOSIS; CELL TRANSFORMATION; CPG ISLAND; DNA MICROARRAY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL MODEL; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LUCIFERASES; MICRORNAS; MODELS, STATISTICAL; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PANCREATIC NEOPLASMS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION; UP-REGULATION;

EID: 84857468335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032068     Document Type: Article

References (79)

1. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M, (2008) MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 12: 2171-2176.
2. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, et al. (2008) Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clinical chemistry 54: 1716-1724.
3. Goggins M, (2007) Identifying molecular markers for the early detection of pancreatic neoplasia. Seminars in oncology 34: 303-310.
4. Mukherjee S, Hudson E, Reza S, Thomas M, Crosby T, et al. (2008) Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer. Clin Oncol (R Coll Radiol) 20: 535-540.
5. Bellizzi AM, Stelow EB, (2009) Pancreatic cytopathology: a practical approach and review. Arch Pathol Lab Med 133: 388-404.
6. Warshaw AL, Fernandez-del Castillo C, (1992) Pancreatic carcinoma. N Engl J Med 326: 455-465.
7. Chua YJ, Cunningham D, (2005) Adjuvant Treatment for Resectable Pancreatic Cancer. J Clin Oncol 23: 4532-4537.
8. Garcea G, Ong SL, Rajesh A, Neal CP, Pollard CA, et al. (2008) Cystic lesions of the pancreas. A diagnostic and management dilemma. Pancreatology 8: 236-251.
9. Matthaei H, Schulick RD, Hruban RH, Maitra A, (2011) Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol 8: 141-150.
10. Galanis C, Zamani A, Cameron J, Campbell K, Lillemoe K, et al. (2007) Resected Serous Cystic Neoplasms of the Pancreas: A Review of 158 Patients with Recommendations for Treatment. Journal of Gastrointestinal Surgery 11: 820-826.
11. Klimstra DS, Pitman MB, Hruban RH, (2009) An algorithmic approach to the diagnosis of pancreatic neoplasms. Arch Pathol Lab Med 133: 454-464.
12. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, et al. (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6: 17-32.
13. Stefano C, Carlos Fernández-del C, Roberto S, Dianne F, Claudio B, et al. (2010) Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 8: 213-219.e214.
14. Basturk O, Coban I, Adsay NV, (2009) Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med 133: 423-438.
15. Sahani DV, Miller JC, del Castillo CF, Brugge WR, Thrall JH, et al. (2009) Cystic pancreatic lesions: classification and management. J Am Coll Radiol 6: 376-380.
16. Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw AL, (2004) Cystic neoplasms of the pancreas. N Engl J Med 351: 1218-1226.
17. Reddy S, Wolfgang CL, (2007) Benign pancreatic tumors. Surg Clin North Am 87: 1359-1378, viii.
18. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, et al. (2009) The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A 106: 15732-15737.
19. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, et al. (2007) MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452.
20. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, et al. (2007) MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908.
21. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, et al. (2010) MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 9: 169.
22. Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, et al. (2011) MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer. Ann Surg Oncol.
23. Wang H, Ach RA, Curry B, (2007) Direct and sensitive miRNA profiling from low-input total RNA. RNA 13: 151-159.
24. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ, (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucl Acids Res 34: D140-144.
25. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ, (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-158.
26. Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, et al. (2009) miRNAs in lung cancer- studying complex fingerprints in patient's blood cells by microarray experiments. BMC cancer 9: 353.
27. Vorwerk S, Ganter K, Cheng Y, Hoheisel J, Stahler PF, et al. (2008) Microfluidic-based enzymatic on-chip labeling of miRNAs. N Biotechnol 25: 142-149.
28. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, et al. (2010) Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 24: 2754-2759.
29. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
30. Bartley AN, Yao H, Barkoh BA, Ivan C, Mishra BM, et al. (2011) Complex Patterns of Altered MicroRNA Expression during the Adenoma-Adenocarcinoma Sequence for Microsatellite-Stable Colorectal Cancer. Clin Cancer Res 17: 7283-7293.
31. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
32. Smyth GK, Michaud J, Scott HS, (2005) Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21: 2067-2075.
33. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society 57: 289-300.
34. Hochberg Y, (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75: 800-802.
35. Selcuklu SD, Donoghue MT, Spillane C, (2009) miR-21 as a key regulator of oncogenic processes. Biochemical Society transactions 37: 918-925.
36. Krichevsky AM, Gabriely G, (2009) miR-21: a small multi-faceted RNA. Journal of Cellular and Molecular Medicine 13: 39-53.
37. Meister J, Schmidt MH, (2010) miR-126 and miR-126*: new players in cancer. ScientificWorldJournal 10: 2090-2100.
38. Aqeilan RI, Calin GA, Croce CM, (2010) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220.
39. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, et al. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
40. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, et al. (1996) bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 2: 2015-2022.
41. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, et al. (2009) An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 15: 1163-1169.
42. Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, et al. (2003) An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 89: 2104-2109.
43. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, et al. (2009) HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 174: 854-868.
44. Chen X, Guo X, Zhang H, Xiang Y, Chen J, et al. (2009) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28: 1385-1392.
45. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102: 13944-13949.
46. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, et al. (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277.
47. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, et al. (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187.
48. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, et al. (2008) MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373: 607-612.
49. Feng R, Chen X, Yu Y, Su L, Yu B, et al. (2010) miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 298: 50-63.
50. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS, (2009) Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene 28: 4272-4283.
51. Torrisani J, Bournet B, du Rieu MC, Bouisson M, Souque A, et al. (2009) let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Human Gene Therapy 20: 831-844.
52. Oh JS, Kim JJ, Byun JY, Kim IA, (2010) Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 76: 5-8.
53. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
54. Akao Y, Nakagawa Y, Naoe T, (2006) let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29: 903-906.
55. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, et al. (2011) A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12: 377-386.
56. Miranda KC, Huynh T, Tay Y, Ang Y-S, Tam W-L, et al. (2006) A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes. Cell 126: 1203-1217.
57. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, et al. (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105.
58. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, et al. (2009) miR-24 Inhibits Cell Proliferation by Targeting E2F2, MYC, and Other Cell-Cycle Genes via Binding to Seedless 32UTR MicroRNA Recognition Elements. Molecular Cell 35: 610-625.
59. Seux M, Iovanna J, Dagorn JC, Dusetti NJ, (2009) MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues. Pancreatology: official journal of the International Association of Pancreatology (IAP) [et al] 9: 66-72.
60. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, et al. (2010) MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 56: 603-612.
61. Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, et al. (2009) MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer biology & therapy 8: 340-346.
62. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
63. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, et al. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104: 15805-15810.
64. Mayr C, Hemann MT, Bartel DP, (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-1579.
65. Friedlander SYG, Chu GC, Snyder EL, Girnius N, Dibelius G, et al. (2009) Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras. Cancer Cell 16: 379-389.
66. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, et al. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500.
67. Bartsch D, Bastian D, Barth P, Schudy A, Nies C, et al. (1998) K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. Ann Surg 228: 79-86.
68. Ishikawa T, Nakao A, Nomoto S, Hosono J, Harada A, et al. (1998) Immunohistochemical and molecular biological studies of serous cystadenoma of the pancreas. Pancreas 16: 40-44.
69. Yoshizawa K, Nagai H, Sakurai S, Hironaka M, Morinaga S, et al. (2002) Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas. Virchows Arch 441: 437-443.
70. Satoh K, Sawai T, Shimosegawa T, Koizumi M, Yamazaki T, et al. (1991) [Point mutation of c-k-ras oncogene at codon 12 in mucin-producing cystic tumor of the pancreas]. Nihon Shokakibyo Gakkai Zasshi 88: 2795-2803.
71. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, et al. (2007) Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11: 229-243.
72. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529.
73. Xia L, Zhang D, Du R, Pan Y, Zhao L, et al. (2008) miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123: 372-379.
74. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, et al. (2009) MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 69: 9090-9095.
75. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, et al. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152.
76. Mardin WA, Mees ST, (2009) MicroRNAs: Novel Diagnostic and Therapeutic Tools for Pancreatic Ductal Adenocarcinoma? Annals of surgical oncology.
77. Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, et al. (2011) MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res.
78. Yu S, Lu Z, Liu C, Meng Y, Ma Y, et al. (2010) miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 70: 6015-6025.
79. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM, et al. (2010) The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 31: 1726-1733.